The Gerald J. Glasser Brain Tumor Center offers patients hope through a robust clinical trial research program. Researchers are working to discover the next generation of brain tumor treatments.
This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. These brain metastases often have altered or mutated genes. Medications that target these genes may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
For Patients With Locally Advanced or Metastatic Solid Tumors
The objective of this study is to evaluate the efficacy of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with recurrent high-grade glioma (HGG) harboring BRAF V600E mutation. This will be conducted as two single arm open-label subprotocols (F8394-201A; F8394-201B) under one master protocol.
Learn more about this trial >
For Newly-Diagnosed Patients with Glioblastoma Multiform (GBM)
Patients Newly Diagnosed H3 K27M-mutant Gliomas
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
For patients with Recurrent or Progressive grade 3 or 4 gliomas with IDH1 Mutation
This multi-site, Phase 1/2a clinical trial is an open label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with radiographically-confirmed progression of Grade IV glioma or recurrent primary or secondary Grade IV glioma or patients with progressed or recurrent Grade III glioma.
For patients with H3-K27M-mutant and/or Midline Gliomas
This is an intermediate-size expanded access protocol to provide ONC201 (dordaviprone) to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 (dordaviprone) through clinical trials.